Substrate-labeled fluorescent immunoassay for amikacin in human serum
| Autor: | S G Thompson, J F Burd |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1980 |
| Předmět: |
Radioimmunoassay
Fluorescent Antibody Technique Binding Competitive Substrate Specificity Hydrolysis Kanamycin medicine polycyclic compounds otorhinolaryngologic diseases Humans Pharmacology (medical) Amikacin Pharmacology Antiserum chemistry.chemical_classification Chromatography Immune Sera Substrate (chemistry) biochemical phenomena metabolism and nutrition bacterial infections and mycoses Fluorescence carbohydrates (lipids) Infectious Diseases Enzyme Biochemistry chemistry Conjugate medicine.drug Research Article |
| Popis: | A homogeneous substrate-labeled fluorescent immunoassay has been developed to measure amikacin levels in human serum. Amikacin is covalently labeled with the fluorogenic enzyme substrate beta-galactosyl-umbelliferone. This beta-galactosyl-umbelliferone-amikacin conjugate is nonfluorescent under assay conditions until it is hydrolyzed by beta-galactosidase to yield a fluorescent product. When antiserum to amikacin binds the substrate-labeled drug, the antibody complex formation inhibits hydrolysis of the fluorogenic substrate. Reaction mixtures containing a constant level of substrate-labeled amikacin and a limiting amount of antiserum enable labeled and unlabeled amikacin to compete for the antibody-binding sites. Unbound substrate-labeled drug is hydrolyzed by the enzyme to release a fluorescent product that is proportional to the unlabeled amikacin concentration. The amikacin levels found in clinical serum samples with this method were comparable (r = 0.987) to those obtained by radioimmunoassay. The fluorescent immunoassay is rapid and simple to perform and requires only 2 microliters of serum. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|